The board of directors of TOT BIOPHARM International Company Limited announced that, with effect from 12 March 2022: Dr. Kung, Frank Fang-Chien has resigned from his role as a non-executive director of the Company due to adjustments to his personal work responsibilities; Mr. Kang, Pei has resigned from his roles as a non-executive director of the Company and a member of the Remuneration Committee due to his desire to devote more energy to his work in other fields; and Dr. Sun, Lijun Richard has resigned from his roles as an independent non-executive director of the Company and a member of each of the Remuneration Committee, the Nomination Committee, and the Strategy and ESG Committee due to the expiration of his three-year term of appointment and his intention to not renew the appointment by reason of personal affairs arrangements. The Board announced that Dr. Wang, De Qian has been appointed as an independent non-executive director of the Company, with effect from 12 March 2022. Mr. Chang, Hong-Jen has been appointed as a member of the Remuneration Committee, and has ceased to be the chairman of the Remuneration Committee and a member of the Strategy and ESG Committee; Mr. Qiu, Yu Min has been appointed as the chairman of the Remuneration Committee and a member of the Strategy and ESG Committee; and Dr. Wang has been appointed as a member of each of the Remuneration Committee, the Nomination Committee, and the Strategy and ESG Committee.